There is a revolution in the works for influenza vaccines. Relatively poor efficacy over the past decade combined with the use of cumbersome egg-based manufacturing and the need to change vaccine strains regularly is driving significant changes in the influenza vaccine industry. Efforts include use of recombinant hemagglutinin and virus-like particles with broader, more robust coverage, inclusion and control of neuraminidase and other influenza virus proteins, and, of course, multivalent mRNA vaccines. These new approaches demand a concurrent revolution in Critical Quality Attribute (CQA) testing, with a long-overdue departure from the use of decades old, inefficient methods such as single radial immunodiffusion.
In this webinar, our speaker Dr. Erica Dawson, Chief Technology Officer of InDevR, will describe how InDevR is supporting influenza vaccine development and production by enabling unprecedented efficiency in CQA testing throughout the bioprocess and multivalent Drug Product.
Dr. Dawson earned her Ph.D. in Analytical Chemistry from The University of North Carolina at Chapel Hill, holds a B.S. from Hartwick College in Oneonta, NY, and completed her postdoctoral training at the University of Colorado at Boulder. Erica has published a wide number of high impact scientific publications and is a named inventor on numerous issued or pending US and worldwide patents. She has been integral in leading the research and development and transfer to manufacturing of InDevR products since 2006.
Dr. Dawson will discuss:
• Efficient non-SRID based identity, quantity, and stability kits for hemagglutinin
• Reagent kits for neuraminidase identity and quantity testing (accepted by USFDA and Health Canada)
• Robust quantification of nucleoprotein
• New tools for identity, quantity, and stability testing of mRNA vaccines
A live Q&A session will follow the presentation, offering you a chance to pose questions to our speaker.